Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIA study of icotinib in various solid tumors, mainly advanced non-small cell lung cancer
ChiCTR-TNRC-08000194Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of icotinib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (6 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Progression-free survival and Safety and tolerance. Started Nov 2007; status: completed.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR-TNRC-08000194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-08000194.